129742938852343750_194Hisun pharmaceutical industry (600,267): sea further in cooperation with Pfizer Pharmaceuticals and Pfizer signed on June 30
star wars the gold republic credits, 2011 bulletin, of the joint venture letter of intent on jointly funded venture reached a preliminary intention. On February 20, 2012, the Sea Bulletin and Pfizer Luxembourg signed the joint venture framework agreement
tsw gold, proposed the "sea-GuideSwiss pharmaceutical company ", a total investment of $ 295 million, hisun pharmaceutical industry shares 51% (cash assets), the Pfizer unit 49% (mainly for cash). Haizheng and Pfizer respectively some of their own products into the joint venture company. Specific project implementation needs to sign a formal contract. Investment needs of the projects submitted to the company's Board of Directors and shareholders ' approval of the General Assembly for its consideration, and be subject in ChinaRelevant government departments for approval. Views: establishing depth cooperation with global pharmaceutical giants, Chinese chemicals (601,117) pharmaceutical companies achieve industrial upgrading one of the paths, and continue to increase input into the Chinese market, is a multinational pharmaceutical company consistent objective. As far as the cooperation between the two sides, haizheng fancy Pfizer Global research and development product line and marketing realPfizer looking at sea are into international goals and �C in line with the efforts of Europe and of standard hardware construction and product supply, are expected to achieve a win-win situation between the two sides, but require a break-in period.
����After the founding of joint venture company, short-term domestic brand generic drugs, long-term Pfizer is expected to become the sea are agents important export partner. Hisun pharmaceutical industry after a few years ago a large number ofInvestment, emerging industrial upgrading routes, and began to enter the harvest period
eq2 platinum, performance is expected to continue into profit growth in income growth, and with the 2012 contract customization step by step confirmation, revenue is expected to gradually accelerate: 1) upgrade paths clear, results-driven factors continue to enrich: prior to 2007: rely on raw material export 2007-2010:Preparation in rapid scale; 2011-2013: dramatic growth in the custom contract, become a carriage driving growth; after 2013: implementing agents independent exports, genetic engineering and innovative drugs listed step by step. 2) brought about by the performance drivers continue to enrich "continued high growth". 3) maintain the "recommended" rating. Taking into account the 3 raw materialsMedicine 2012 the fastest production line put into operation in the first half, before 2012 corporate performance is expected to be high. Maintain performance prediction 11-13EPS, 0.97, 1.62, an increase of 40%/30%/28%, 11-13PE29/22/17, one-year target price of 36-39 million (12PE28~30X���� (Guosen Securities Research Institute)
